Table 1 Summary of patient demographic data, lesion type, treatment regimen and geographic atrophy progression

Injections received

81 ranibizumab

–

18 ranibizumab; 36 aflibercept

–

51 ranibizumab

–

6 bevacizumab; 70 ranibizumab

–

NV

Type 1

–

Type 1

–

Type 1

–

Type 1

–

Regimen schedule

q6 weeks

–

q6–7 weeks

–

q7–8 weeks

–

q4–5 weeks

–

Total follow-up interval

120 months

62 months

99 months

95 months

Initial visit (mm²)

0.38

0.05

0.00

0.00

0.00

0.00

0.56

4.62

Last visit (mm²)

1.73

9.65

0.30

6.72

0.07

5.72

0.61

7.84

ΔGA _{Last − Initial}

1.35

9.60

0.30

6.72

0.07

5.72

0.05

3.22

Progression rate 1 of GA (mm²/month)

0.01125

0.08

0.00483

0.10838

0.00070

0.05777

0.00052

0.03389

Progression rate 2 of GA (mm²/injection)

0.01666

–

0.00555

–

0.00137

–

0.00065

–